Today: 11 June 2026
Chevron (CVX) stock holds steady after report puts it in $22 billion Lukoil asset race
13 January 2026
2 mins read

Chevron (CVX) stock holds steady after report puts it in $22 billion Lukoil asset race

New York, Jan 12, 2026, 19:30 EST — After-hours

Chevron Corp shares nudged up 0.2% in after-hours Monday, closing at $162.34. The stock held firm after Reuters reported that Chevron, paired with private-equity firm Quantum Capital Group, is among the top contenders to acquire Lukoil’s $22 billion overseas portfolio. This includes oil fields in Iraq, Azerbaijan, Kazakhstan, plus refineries and fuel stations across Europe and the U.S., all ahead of a Jan. 17 U.S. deadline. Also bidding are private equity heavyweight Carlyle and Abu Dhabi’s International Holding Company. Any deal would require approval from the U.S. Treasury’s Office of Foreign Assets Control (OFAC), which has already blocked two previous attempts, according to the report.

Why it matters now: the deadline squeezes a sprawling, complicated sale into just days instead of weeks, thrusting Washington’s sanctions watchdogs into the heart of a $22 billion deal. For Chevron investors, that’s the crux — even routine M&A can become a high-stakes gamble once sanctions come into play.

The backdrop isn’t exactly stable. Crude surged on supply concerns, yet the market is grappling with predictions of increased output and weaker prices heading into 2026. This push and pull hits Big Oil stocks hard and fast.

Brent closed 0.8% higher Monday, hitting $63.87 a barrel. U.S. West Texas Intermediate finished at $59.50. Concerns over Iran’s exports pushed prices up, though anticipated increases in Venezuelan supply capped the rally, Reuters reported.

Goldman Sachs advised clients that Brent is still expected to average $56 a barrel and WTI $52 in 2026. The firm warned of a 2.3 million barrels-per-day surplus that could push prices down as the market seeks balance. It described the risks to its forecast as “modestly” tilted to the downside and recommended oil producers hedge their 2026 price exposure. Reuters

Chevron is caught up in another major sanctions story: Venezuela. Traders Vitol and Trafigura have scored preliminary licenses to negotiate and export Venezuelan crude, Reuters reported, as Washington pushes to resume shipments. Chevron — the sole U.S. oil major operating there under a U.S. license — vied for those supply deals. Meanwhile, Exxon CEO Darren Woods branded Venezuela “uninvestable” without serious security and legal reforms. Reuters

Chevron Vice Chairman Mark Nelson told Trump the company could boost its Venezuela output by 50% within two years, starting from roughly 240,000 barrels per day (bpd), by upgrading existing equipment, according to a Reuters analysis.

Energy stocks showed mixed moves after hours. Exxon dipped 0.5%, BP gained roughly 0.4%, and ConocoPhillips dropped around 2.1%.

Chevron’s modest step on Monday came off more like a shrug than a wager. Traders are waiting to see how price and structure hold up, plus whether any deal can pass OFAC scrutiny — all before debates kick off over the true value of a sanctioned portfolio amid softer oil prices.

Chevron plans to release its fourth-quarter earnings on Jan. 30, with a conference call scheduled for 11 a.m. ET, per the company’s events calendar.

But the Lukoil plan might still fall apart: OFAC could deny a licence or impose conditions that undercut the economics. Sanctioned assets carry real headaches—from banking hurdles to shipping complications. If crude prices dip later this year, cash flows across the sector will tighten, making it tougher to justify any major acquisition to shareholders.

Traders eye Tuesday for any follow-through on the Lukoil auction, while crude looks to maintain its recent gains. Chevron’s next big event is its earnings call set for Jan. 30.

Stock Market Today

  • What is an IPO as SpaceX Prepares for U.S. Stock Market Debut
    June 10, 2026, 6:01 PM EDT. An IPO, or Initial Public Offering, is when a private company sells shares to the public for the first time, becoming publicly traded. SpaceX, the aerospace manufacturer, is expected to make its debut on the U.S. stock market, marking one of the most anticipated IPOs in recent years. This move allows retail and institutional investors to buy equity in SpaceX, potentially impacting the space industry and tech sectors. The IPO process involves regulatory filings, pricing, and public trading, providing companies with capital for expansion. SpaceX's offering could reshape market dynamics, drawing significant investor interest given its innovations and growth trajectory.

Latest articles

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

10 June 2026
Parabilis Medicines soared 58% above its $20 IPO price to close at $31.60 in its Nasdaq debut after raising a record $670 million, reflecting strong investor demand for its Helicon drug platform ahead of a pivotal Phase 3 desmoid tumor trial planned for 2027; Regeneron’s $75 million private placement added credibility.
Joby Aviation Shares Slip After CFO Files to Sell Stock

Joby Aviation Shares Slip After CFO Files to Sell Stock

10 June 2026
Joby Aviation fell 4.47% to $8.86 after CFO Rodrigo Brumana disclosed selling 78,489 shares under a prearranged 10b5-1 plan, with no new certification or commercial-launch updates, leaving investors focused on regulatory progress and cash burn as the key catalysts for the stock.
YY Group Shares Spike as Humanoid Robot Plans Unveiled

YY Group Shares Spike as Humanoid Robot Plans Unveiled

10 June 2026
YY Group Holding shares surged to $0.165 on heavy volume after announcing a commercial humanoid-robotics initiative using Unitree G1 robots and facility-management data, reframing the company as a robotics-and-AI data play; the rally comes despite 2025 net loss, dilution risk from a relaunched at-the-market share-sale program, and no disclosed robot-related revenue or contracts.
Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal
Previous Story

Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal

Locked out of $22B: Canadian real estate funds freeze withdrawals as gates spread
Next Story

Locked out of $22B: Canadian real estate funds freeze withdrawals as gates spread

Go toTop